Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology

Neuropsychopharmacology

Volumn 39, Issue 1, 2014, Pages 24-33

  Wood, Paul L ^a  

^a LINCOLN MEMORIAL UNIVERSITY   (United States)

Author keywords

autism; glioblastoma; metabolomics; plasmalogens; schizophrenia; sulfatides

Indexed keywords

PLASMALOGEN; SULFUR AMINO ACID; BIOLOGICAL MARKER; LIPID;

ALZHEIMER DISEASE; AMINO ACID METABOLISM; AMYOTROPHIC LATERAL SCLEROSIS; AUTISM; DISEASE COURSE; FAMILIAL DISEASE; GLIOBLASTOMA; HUMAN; LIPIDOMICS; MASS SPECTROMETRY; METABOLOMICS; MICRODIALYSIS; NEUROLOGY; ONCOLOGY; PRIORITY JOURNAL; PSYCHIATRY; REVIEW; SCHIZOPHRENIA; STEADY STATE; LIPID METABOLISM; MENTAL DISEASE; METABOLISM; NEUROLOGIC DISEASE; PROCEDURES; TRANSLATIONAL RESEARCH;

BIOLOGICAL MARKERS; HUMANS; LIPID METABOLISM; LIPIDS; MASS SPECTROMETRY; MEDICAL ONCOLOGY; MENTAL DISORDERS; METABOLOMICS; NERVOUS SYSTEM DISEASES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84890444970     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.167     Document Type: Review

References (95)

1. Abu-Asab MS, Chaouchi M, Alesci S, Galli S, Laassri M, Cheema AK et al (2011). Biomarkers in the age of omics: Time for a systems biology approach. OMICS 15: 105-112
2. Adams JB, Audhya T, McDonough-Means S, Rubin RA, Quig D, Geis E et al (2011). Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity. Nutr Metab (Lond) 8: 34
3. Alberti A, Pirrone P, Elia M, Waring RH, Romano C (1999). Sulphation deficit in 'low-functioning' autistic children: A pilot study. Biol Psychiatry 46: 420-424
4. Al-Ayadhi L, Halepoto DM (2013). Role of proteomics in the discovery of autism biomarkers. J Coll Physicians Surg Pak 23: 137-143
5. Altuntas I, Aksoy H, Coskun I, CayköylüA, Akçay F (2000). Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med 38: 1277-1281
6. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E et al (2010). Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS ONE 5: E12538
7. Bazenet C, Lovestone S (2012). Plasma biomarkers for Alzheimer's disease: Much needed but tough to find. Biomark Med 6: 441-454
8. Bianchi L, De Micheli E, Bricolo A, Ballini C, Fattori M, Venturi C et al (2004). Extracellular levels of amino acids and choline in human high grade gliomas: An intraoperative microdialysis study. Neurochem Res 29: 325-334
9. Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA (1985). Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry 147: 276-282
10. Bowling FG, Heussler HS, McWhinney A, Dawson PA (2012). Plasma and urinary sulfate determination in a cohort with autism. Biochem Genet 51: 147-153
11. Britton LM, Gonzales-Cope M, Zee BM, Garcia BA (2011). Breaking the histone code with quantitative mass spectrometry. Expert Rev Proteomics 8: 631-643
12. Bullinger D, Neubauer H, Fehm T, Laufer S, Gleiter CH, Kammerer B (2007). Metabolic signature of breast cancer cell line MCF-7: Profiling of modified nucleosides via LC-IT MS coupling. BMC Biochem 8: 25
13. Ciccimaro E, Blair IA (2010). Stable-isotope dilution LC-MS for quantitative biomarker analysis. Bioanalysis 2: 311-341
14. Costa E, Chen Y, Dong E, Grayson DR, Kundakovic M, Maloku E et al (2009). GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability. Expert Rev Neurother 9: 87-98
15. Creek DJ, Chokkathukalam A, Jankevics A, Burgess KE, Breitling R, Barrett MP (2012). Stable isotope-Assisted metabolomics for network-wide metabolic pathway elucidation. Anal Chem 84: 8442-8447
16. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K et al (2004). Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 101: 2070-2075
17. Deng H, Tang X, Wang H, Tang G, Wen F, Shi X et al (2011). S-11Cmethyl-L-cysteine: A new amino acid PET tracer for cancer imaging. J Nucl Med 52: 287-293
18. Dietrich-Muszalska A, Malinowska J, Olas B, G"owacki R, Bald E, Wachowicz B et al (2012). The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem Res 37: 1057-1062
19. Dudley E, Yousef M, Wang Y, Griffiths WJ (2010). Targeted metabolomics and mass spectrometry. Adv Protein Chem Struct Biol 80: 45-83
20. Emary WB, Lys I, Cotter RJ, Simpson R, Hoffman A (1990). Liquid chromatography/ time-of-flight mass spectrometry with high-speed integrated transient recording. Anal Chem 62: 1319-1324
21. Emmett MR, André n PE, Caprioli RM (1995). Specific molecular mass detection of endogenously released neuropeptides using in vivo microdialysis/mass spectrometry. J Neurosci Methods 62: 141-147
22. Erten-Lyons D, Woltjer RL, Dodge H, Nixon R, Vorobik R, Calvert JF et al (2009). Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 72: 354-360
23. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM (1989). Electrospray ionization for mass spectrometry of large biomolecules. Science 246: 64-71
24. Florent-Bé chard S, Desbène C, Garcia P, Allouche A, Youssef I, Escanyé MC et al (2009). The essential role of lipids in Alzheimer's disease. Biochimie 91: 804-809
25. Frankhauser P, Grimmer Y, Bugert P, Deuschle M, Schmidt M, Schloss P (2006). Characterization of the neuronal dopamine transporter DAT in human blood platelets. Neurosci Lett 399: 197-201
26. Gates SC, Dendramis N, Sweeley CC (1978). Automated metabolic profiling of organic acids in human urine. I. Description of methods. Clin Chem 24: 1674-1679
27. Gates SC, Sweeley CC, Krivit W, DeWitt D, Blaisdell BE (1978). Automated metabolic profiling of organic acids in human urine. II. Analysis of urine samples from 'healthy' adults, sick children, and children with neuroblastoma. Clin Chem 24: 1663-1673
28. Geier DA, Geier MR (2006). A clinical and laboratory evaluation of methionine cycletranssulfuration and androgen pathway markers in children with autistic disorders. Horm Res 66: 182-188
29. Geier DA, Kern JK, Garver CR, Adams JB, Audhya T, Geier MR (2009). A prospective study of transsulfuration biomarkers in autistic disorders. Neurochem Res 34: 386-393
30. Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL (1995). Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res 698: 223-226
31. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW et al (2007). Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer's disease and dementia. J Lipid Res 48: 2485-2498
32. Grimm MO, Kuchenbecker J, Rothhaar TL, Grösgen S, Hundsdörfer B, Burg VK et al (2011). Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer's disease. J Neurochem 116: 916-925
33. Gründemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R et al (2005). Discovery of the ergothioneine transporter. Proc Natl Acad Sci USA 102: 5256-5261
34. Gysin R, Kraftsik R, Boulat O, Bovet P, Conus P, Comte-Krieger E et al (2011). Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. Antioxid Redox Signal 15: 2003-2010
35. Han X, Holtzman DM, McKeel DW Jr (2001). Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: Molecular characterization using electrospray ionization mass spectrometry. J Neurochem 77: 1168-1180
36. Han X, M Holtzman D, McKeel DW Jr, Kelley J, Morris JC (2002). Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: Potential role in disease pathogenesis. J Neurochem 82: 809-818
37. Han X (2005). Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: Implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2: 65-77
38. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR et al (2011). Metabolomics in early Alzheimer's disease: Identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE 6: E21643
39. Havemeyer A, Lang J, Clement B (2011). The fourth mammalian molybdenum enzyme mARC: Current state of research. Drug Metab Rev 43: 524-539
40. He X, Huang Y, Li B, Gong CX, Schuchman EH (2010). Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 31: 398-408
41. Hu Q, Noll RJ, Li H, Makarov A, Hardman M, Graham Cooks R (2005). The Orbitrap: A new mass spectrometer. J Mass Spectrom 40: 430-443
42. Hu CW, Liu HH, Li YJ, Chao MR (2012). Direct analysis of 5-methylcytosine and 5-methyl-2'-deoxycytidine in human urine by isotope dilution LC-MS/MS: Correlations with N-methylated purines and oxidized DNA lesions. Chem Res Toxicol 25: 462-470
43. Izumi Y, Takimura S, Yamaguchi S, Iida J, Bamba T, Fukusaki E (2012). Application of electrospray ionization ion trap/time-of-flight mass spectrometry for chemically-synthesized small RNAs. J Biosci Bioeng 113: 412-419
44. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW et al (2004). Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80: 1611-1617
45. Kern JK, Geier DA, Adams JB, Garver CR, Audhya T, Geier MR (2011). A clinical trial of glutathione supplementation in autism spectrum disorders. Med Sci Monit 17: CR677-CR682
46. Kim TH, Moon SW (2011). Serum homocysteine and folate levels in korean schizophrenic patients. Psychiatry Investig 8: 134-140
47. Koal T, Deigner HP (2010). Challenges in mass spectrometry based targeted metabolomics. Curr Mol Med 10: 216-226
48. Kotthaus J, Wahl B, Havemeyer A, Kotthaus J, Schade D, Garbe-Schönberg D et al (2011). Reduction of N(o)-hydroxy-L-Arginine by the mitochondrial amidoxime reducing component (mARC). Biochem J 433: 383-391
49. Kou J, Kovacs GG, Höftberger R, Kulik W, Brodde A, Forss-Petter S et al (2011). Peroxisomal alterations in Alzheimer's disease. Acta Neuropathol 122: 271-283
50. Krone N, Hughes BA, Lavery GG, Stewart PM, Arlt W, Shackleton CH (2010). Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). J Steroid Biochem Mol Biol 121: 496-504
51. Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE et al (2012). Biochemical alterations associated with ALS. Amyotroph Lateral Scler 13: 110-118
52. Lin H (2011). S-Adenosylmethionine-dependent alkylation reactions: When are radical reactions used? Bioorg Chem 39: 161-170
53. Maarouf CL, Daugs ID, Kokjohn TA, Walker DG, Hunter JM, Kruchowsky JC et al (2011). Alzheimer's disease and non-demented high pathology control nonagenarians: Comparing and contrasting the biochemistry of cognitively successful aging. PLoS ONE 6: E27291
54. Marshall AG, Hendrickson CL, Jackson GS (1998). Fourier transform ion cyclotron resonance mass spectrometry: A primer. Mass Spectrom Rev 17: 1-35
55. McLafferty FW (1981). Tandem mass spectrometry. Science 214: 280-287
56. Mielke MM, Haughey NJ, Ratnam Bandaru VV, Schech S, Carrick R, Carlson MC et al (2010). Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement 6: 378-385
57. Mishur RJ, Rea SL (2012). Applications of mass spectrometry to metabolomics and metabonomics: Detection of biomarkers of aging and of age-related diseases. Mass Spectrom Rev 31: 70-95
58. Morris SE, Cuthbert BN (2012). Research Domain Criteria: Cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin Neurosci 14: 29-37
59. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M (2006). Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: A meta-Analysis. Mol Psychiatry 11: 143-149
60. Nicholson JK, Lindon JC, Holmes E (1999). 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29: 1181-1189
61. Nordström A, Lewensohn R (2010). Metabolomics: Moving to the clinic. J Neuroimmune Pharmacol 5: 4-17
62. Oreš ič M, Tang J, Seppä nen-Laakso T, Mattila I, Saarni SE, Saarni SI et al (2011). Metabolome in schizophrenia and other psychotic disorders: A general population-based study. Genome Med 3: 19
63. Paşca SP, Dronca E, Kaucsá r T, Craciun EC, Endreffy E, Ferencz BK et al (2009). One carbon metabolism disturbances and the C677T MTHFR gene polymorphism in children with autism spectrum disorders. J Cell Mol Med 13: 4229-4238
64. Pastural E, Ritchie S, Lu Y, Jin W, Kavianpour A, Khine Su-Myat K et al (2009). Novel plasma phospholipid biomarkers of autism: Mitochondrial dysfunction as a putative causative mechanism. Prostaglandins Leukot Essent Fatty Acids 81: 253-264
65. Pean A, Steventon GB, Waring RH, Foster H, Sturman S, Williams AC (1994). Pathways of cysteine metabolism in MND/ALS. J Neurol Sci 124(Suppl): 59-61
66. Postle AD (2012). Lipidomics. Curr Opin Clin Nutr Metab Care 15: 127-133
67. Regland B (2005). Schizophrenia and single-carbon metabolism. Prog. Neuropsychopharmacol Biol Psychiatry 29: 1124-1132
68. Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G et al (2011). A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 118: 449-457
69. Rouault TA (2012). Biogenesis of iron-sulfur clusters in mammalian cells: New insights and relevance to human disease. Dis Model Mech 5: 155-164
70. Satoi H, Tomimoto H, Ohtani R, Kitano T, Kondo T, Watanabe M et al (2005). Astroglial expression of ceramide in Alzheimer's disease brains: A role during neuronal apoptosis. Neuroscience 130: 657-666
71. Schuhmann K, Almeida R, Baumert M, Herzog R, Bornstein SR, Shevchenko A (2012). Shotgun lipidomics on a LTQ Orbitrap mass spectrometer by successive switching between acquisition polarity modes. J Mass Spectrom 47: 96-104
72. Stricker NH, Schweinsburg BC, Delano-Wood L, Wierenga CE, Bangen KJ, Haaland KY et al (2009). Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer's disease supports retrogenesis. Neuroimage 45: 10-16
73. Strous RD, Golubchik P, Maayan R, Mozes T, Tuati-Werner D, Weizman A et al (2005). Lowered DHEA-S plasma levels in adult individuals with autistic disorder. Eur Neuropsychopharmacol 15: 305-309
74. Suh JH, Walsh WJ, McGinnis WR, Lewis A, Ames BN (2008). Altered sulfur amino acid metabolism in immune cells of children diagnosed with autism. Am J Biochem Biotech 4: 105-113
75. Sun G, Yang K, Zhao Z, Guan S, Han X, Gross RW (2007). Shotgun metabolomics approach for the analysis of negatively charged water-soluble cellular metabolites from mouse heart tissue Shotgun metabolomics approach for the analysis of negatively charged water-soluble cellular metabolites from mouse heart tissue. Anal Chem 79: 6629-6640
76. Valaskovic GA, Utley L, Lee MS, Wu JT. (2006). Ultra-low flow nanospray for the normalization of conventional liquid chromatography/mass spectrometry through equimolar response: Standard-free quantitative estimation of metabolite levels in drug discovery. Rapid Commun Mass Spectrom 20: 1087-1096
77. Vuksan-Ć usa B, Jakovljević M, Sagud M, Mihaljević Peleš A, Marč inko D, Topić R et al (2011). Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics. Psychiatry Res 189: 21-25
78. Waring RH, Klovrza LV (2000). Sulphur metabolism in autism. J Nutrit Envir Med 10: 25-32
79. Wibom C, Surowiec I, Möré n L, Bergström P, Johansson M, Antti H et al (2010). Metabolomic patterns in glioblastoma and changes during radiotherapy: A clinical microdialysis study. J Proteome Res 9: 2909-2919
80. Wood PL (1982). A selected ion monitoring assay for dopamine and its metabolites using negative chemical ionization. Biomed Mass Spectrom 9: 302-306
81. Wood PL, Pé loquin A (1982). ncreases in choline levels in rat brain elicited by meclofenoxate ncreases in choline levels in rat brain elicited by meclofenoxate. Neuropharmacology 21: 349-354
82. Wood PL, Kim HS, Altar CA (1987). In vivo assessment of dopamine and norepinephrine release in rat neocortex: Gas chromatography-mass spectrometry measurement of 3-methoxytyramine and normetanephrine. J Neurochem 48: 574-579
83. Wood PL, Kim HS, Cheney DL, Cosi C, Marien M, Rao TS et al (1988). Constant infusion of [13C6]glucose: Simultaneous measurement of turnover of GABA and glutamate in defined regions of the brain of individual animals. Neuropharmacology 27: 669-676
84. Wood PL, Rao TS (1989). GC-MS and GC-MS/MS of monoamines, indoles, trace amines and their associated precursors and metabolites. In: McEwen CN, Larsen BS (eds.) Mass Spectrometry of Biological Materials. Marcel Dekker: New York, pp 197-214
85. Wood PL, Khan MA, Moskal JR (2006). Neurochemical analysis of amino acids, polyamines and carboxylic acids: GC-MS quantitation of tBDMS derivatives using ammonia positive chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci 831: 313-319
86. Wood PL, Mankidy R, Ritchie S, Heath D, Wood JA, Flax J et al (2010). Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J Psychiatry Neurosci 35: 59-62
87. Wood PL, Khan MA, Smith T, Ehrmantraut G, Jin W, Cui W et al (2011). In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor. Lipids Health Dis 10: 182
88. Wood PL, Smith T, Pelzer L, Goodenowe DB (2011). Targeted metabolomic analyses of cellular models of pelizaeus-merzbacher disease reveal plasmalogen and myo-inositol solute carrier dysfunction. Lipids Health Dis 10: 102
89. Wood PL (2012). Lipidomics of Alzheimer's disease: Current status. Alzheimers Res Ther 4: 5
90. Wood PL, Wood JA (2013). Thiol metabolism in schizophrenia: Current status. Current Psychiatry Rev 9: 136-147
91. Woolsey PB (2008). Cysteine, sulfite, and glutamate toxicity: A cause of ALS? J Altern Complement Med 14: 1159-1164
92. Wuolikainen A, Moritz T, Marklund SL, Antti H, Andersen PM (2011). Diseaserelated changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. PLoS One 6: E17947
93. Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K et al (2013). Potential metabolite markers of schizophrenia. Mol Psychiatry 2011: 1-12
94. Zhang L, Xiao H, Wong DT (2009). Salivary biomarkers for clinical applications. Mol Diagn Ther 13: 245-259
95. Zhubi A, Veldic M, Puri NV, Kadriu B, Caruncho H, Loza I et al (2009). An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophr Res 111: 115-122